PERRONE, GIULIA
 Distribuzione geografica
Continente #
NA - Nord America 1.579
EU - Europa 1.026
AS - Asia 555
AF - Africa 89
SA - Sud America 1
Totale 3.250
Nazione #
US - Stati Uniti d'America 1.576
GB - Regno Unito 290
VN - Vietnam 235
SE - Svezia 196
CN - Cina 180
IT - Italia 130
DE - Germania 128
UA - Ucraina 62
SG - Singapore 58
IN - India 52
IE - Irlanda 45
FR - Francia 43
RU - Federazione Russa 37
TG - Togo 35
CH - Svizzera 30
ZA - Sudafrica 24
EE - Estonia 18
CI - Costa d'Avorio 16
BG - Bulgaria 14
BE - Belgio 11
FI - Finlandia 11
NG - Nigeria 9
IR - Iran 8
JO - Giordania 8
JP - Giappone 6
SC - Seychelles 5
CA - Canada 3
LB - Libano 3
RO - Romania 3
BD - Bangladesh 2
GR - Grecia 2
TR - Turchia 2
CL - Cile 1
CZ - Repubblica Ceca 1
ES - Italia 1
HR - Croazia 1
IL - Israele 1
LT - Lituania 1
NL - Olanda 1
PL - Polonia 1
Totale 3.250
Città #
Southend 268
Chandler 218
Fairfield 183
Ashburn 148
Dong Ket 130
Woodbridge 106
Ann Arbor 83
Seattle 82
Wilmington 77
Houston 75
Cambridge 72
Princeton 59
Singapore 46
Dublin 45
Beijing 43
Jacksonville 39
Bologna 37
Lomé 35
Nanjing 32
Bern 26
Bremen 25
Westminster 25
Padova 24
New York 20
Shenyang 17
Abidjan 16
Jinan 16
Berlin 14
Sofia 14
Turin 14
Hebei 13
Boardman 12
Saint Petersburg 12
Brussels 11
Changsha 11
Helsinki 11
Redwood City 11
Abeokuta 9
Mülheim 9
Santa Clara 9
Amman 8
Nanchang 8
Medford 7
San Diego 7
Verona 7
Jiaxing 6
Monmouth Junction 6
Norwalk 6
Tokyo 6
Washington 6
Mahé 5
Milan 5
Tianjin 5
Ardabil 4
Dearborn 4
Falls Church 4
Lanzhou 4
Paris 4
Pune 4
Redmond 4
Zhengzhou 4
Andover 3
Haikou 3
Hangzhou 3
Kuban 3
Leawood 3
Olalla 3
Sacramento 3
Argelato 2
Boydton 2
Bühl 2
Denver 2
Des Moines 2
Fornovo di Taro 2
Henderson 2
Lausanne 2
Los Angeles 2
Modena 2
Naples 2
Ome 2
San Francisco 2
Sanayi 2
Silverton 2
Taizhou 2
Winnipeg 2
Atlanta 1
Augusta 1
Changchun 1
Dhaka 1
Falkenstein 1
Florence 1
Frankfurt Am Main 1
Frankfurt am Main 1
Groningen 1
Hefei 1
Kilburn 1
London 1
Lyon 1
Madrid 1
Maranello 1
Totale 2.281
Nome #
Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation. 250
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 227
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 167
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 165
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 154
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. 145
Ascorbic acid inhibits antitumor activity of bortezomib in vivo 141
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 136
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. 134
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. 126
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation 122
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. 120
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 120
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 118
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. 117
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 116
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. 114
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 113
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. 107
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 105
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 104
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treatedwith zoledronic acid and thalidomide-dexamethasone. 100
HIF-1a INHIBITION PROMOTES CELL CYCLE ARREST IN MULTIPLE MYELOMA 94
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 93
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 88
Proteasome inhibitors: Bortezomib in multiple myeloma 32
Totale 3.308
Categoria #
all - tutte 7.770
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.770


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020682 0 0 9 61 81 75 91 102 114 56 34 59
2020/2021521 84 28 9 28 15 14 12 25 29 25 46 206
2021/2022606 96 15 32 41 51 34 7 30 20 65 107 108
2022/2023816 88 142 34 130 42 69 24 34 112 25 54 62
2023/2024207 10 32 14 20 25 65 11 5 2 8 6 9
2024/202580 10 57 13 0 0 0 0 0 0 0 0 0
Totale 3.308